McKesson's Strategic Acquisition: What It Means for the Healthcare Sector
McKesson's $2.25 billion acquisition of Precision Medicine Group signals a shift in its strategic focus towards oncology services.
Johnson & Johnson's IMAAVY®: A Game-Changer in the Pharmaceutical Landscape
IMAAVY® marks a significant milestone for Johnson & Johnson, potentially reshaping the market for autoimmune hemolytic anemia treatments.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Trade Tensions Rise: Canada's Response to US Tariffs and Its Impact on TSX-Listed Companies
As trade tensions escalate, Canada's response to US tariffs poses significant implications for TSX-listed companies.
Moderna's Market Reaction: Understanding the Sell-the-News Phenomenon After Positive Trial Results
Despite positive trial results, Moderna's stock dropped 7.32%, highlighting the sell-the-news trend in biotech.
McKesson's $2.25 Billion Precision Medicine Acquisition: What It Means for Investors
McKesson's $2.25 billion acquisition of Precision Medicine Group signals a strategic move in oncology and life sciences.
Trump's Proposed 50% Auto Tariffs: Implications for North American Markets
President Trump's 50% tariff on Canadian auto imports raises concerns for North American markets, signaling potential vo…
Merck and Moderna's mRNA Cancer Vaccine Shows Promise in Phase 3 Trials
Merck and Moderna's mRNA-based cancer vaccine for melanoma shows strong Phase 3 trial results, signaling a shift in canc…
Eli Lilly's FDA Approval: A Game Changer for Alzheimer's Diagnostics
Eli Lilly's recent FDA approval for an Alzheimer's blood test signals a pivotal moment in diagnostics, impacting investo…
Booz Allen Hamilton Strengthens Defense Sector with Ultra I&C Acquisition
Booz Allen Hamilton (BAH) completes acquisition of Ultra I&C, bolstering its defense technology capabilities amid growin…
Merck and Moderna's Phase 3 Success: A Milestone in Cancer Vaccination
Merck and Moderna report significant success in their Phase 3 trial, reinforcing the role of KEYTRUDA in oncology.
Eli Lilly's FDA Approval: A Game Changer for Alzheimer's Diagnostics
Eli Lilly's FDA approval for an Alzheimer's blood test could reshape the diagnostics landscape and boost investor sentim…